brl 42810 has been researched along with Hepatitis B, Chronic in 60 studies
Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with chronic hepatitis B infection and detectable HBV DNA received lamivudine and famciclovir combination therapy." | 9.11 | Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection. ( Alsatie, M; Chalasani, N; Eckert, G; Kwo, PY; Lumeng, L; Shen, H, 2004) |
| "Hepatitis B e antigen-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B (CHBe-) exhibits a high relapse rate on monotherapy with lamivudine or interferon-alpha (IFN-alpha)." | 9.11 | Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. ( Berr, F; Etzrodt, G; Klecker, C; Liebert, UG; Maier, M; Oesen, U; Schiefke, I; Tannapfel, A, 2004) |
| "We examined whether combination therapy with thymosin-alpha1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation." | 9.10 | Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. ( Au, WS; Fong, DY; Hou, J; Kung, HF; Lam, SK; Lau, GK; Lin, M; Nanji, A; Yuen, ST, 2002) |
| "Lamivudine (LMV) is the only nucleoside analogue approved for the treatment of chronic hepatitis B (CHB)." | 7.72 | Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. ( Ayres, A; Bartholomeusz, A; Lam, KC; Lau, G; Lee, JY; Locarnini, S, 2003) |
| "To evaluate the clinical efficacy of combined treatment with lamivudine and famciclovir on chronic hepatitis B virus (HBV) infection." | 7.72 | [Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir]. ( Ji, W; Li, L; Su, HB; Wang, HF, 2003) |
| "We have analyzed the molecular dynamics of emergence of drug-resistant strains in patients receiving lamivudine therapy for chronic hepatitis B." | 7.70 | Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. ( Abidi, H; Ahmed, S; Berby, F; Johnson, M; Merle, P; Nafa, S; Pichoud, C; Stuyver, L; Tavan, D; Trépo, C; Zoulim, F, 2000) |
| "Classic patients with chronic hepatitis B are positive for hepatitis Be-antigen (HBeAg) and HBV-DNA." | 6.42 | Thymosin in the treatment of HBeAg-negative chronic hepatitis B. ( Ozden, N; Saruc, M; Yuceyar, H, 2003) |
| "Patients with chronic hepatitis B infection and detectable HBV DNA received lamivudine and famciclovir combination therapy." | 5.11 | Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection. ( Alsatie, M; Chalasani, N; Eckert, G; Kwo, PY; Lumeng, L; Shen, H, 2004) |
| "Hepatitis B e antigen-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B (CHBe-) exhibits a high relapse rate on monotherapy with lamivudine or interferon-alpha (IFN-alpha)." | 5.11 | Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. ( Berr, F; Etzrodt, G; Klecker, C; Liebert, UG; Maier, M; Oesen, U; Schiefke, I; Tannapfel, A, 2004) |
| "Twelve patients with a history of childhood malignancy and chronic hepatitis B were treated with prednisone for 4 weeks (0." | 5.10 | Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy. ( Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C, 2002) |
| "We examined whether combination therapy with thymosin-alpha1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation." | 5.10 | Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. ( Au, WS; Fong, DY; Hou, J; Kung, HF; Lam, SK; Lau, GK; Lin, M; Nanji, A; Yuen, ST, 2002) |
| "There are two licensed drugs for chronic hepatitis B virus (HBV), interferon alfa and lamivudine, with similar efficacy rates." | 4.81 | How will we use the new antiviral agents for hepatitis B? ( Perrillo, RP, 2002) |
| "After several nucleoside analogues have been tested against chronic hepatitis B virus (HBV) infection with minimal success, lamivudine seems to be a highly effective new therapeutic option." | 4.79 | Experience with lamivudine against hepatitis B virus. ( Jaeckel, E; Manns, MP, 1997) |
| "Lamivudine (LMV) is the only nucleoside analogue approved for the treatment of chronic hepatitis B (CHB)." | 3.72 | Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. ( Ayres, A; Bartholomeusz, A; Lam, KC; Lau, G; Lee, JY; Locarnini, S, 2003) |
| "To evaluate the clinical efficacy of combined treatment with lamivudine and famciclovir on chronic hepatitis B virus (HBV) infection." | 3.72 | [Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir]. ( Ji, W; Li, L; Su, HB; Wang, HF, 2003) |
| "Therapy of chronic hepatitis B virus (HBV) infection with the polymerase inhibitor lamivudine frequently is associated with the emergence of viral resistance." | 3.72 | The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. ( Arnold, E; Das, K; Delaney, WE; Gibbs, CS; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2003) |
| "Treatment for chronic hepatitis B with lamivudine is often hampered by the emergence of point mutations in the YMDD motif of the HBV DNA polymerase gene that confer drug resistance." | 3.72 | Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain. ( Echevarría, JM; León, P; Pozo, F, 2004) |
| "Nucleoside analogues such as lamivudine for chronic hepatitis B have an excellent safety profile while patients are on therapy but reactivation flares occur in 19-50% of patients after stopping therapy, some of whom develop liver decompensation." | 3.71 | Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. ( Guan, R; Kajiji, T; Lim, SG; Rajnakova, A; Wai, CT, 2002) |
| "We have analyzed the molecular dynamics of emergence of drug-resistant strains in patients receiving lamivudine therapy for chronic hepatitis B." | 3.70 | Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. ( Abidi, H; Ahmed, S; Berby, F; Johnson, M; Merle, P; Nafa, S; Pichoud, C; Stuyver, L; Tavan, D; Trépo, C; Zoulim, F, 2000) |
| "Classic patients with chronic hepatitis B are positive for hepatitis Be-antigen (HBeAg) and HBV-DNA." | 2.42 | Thymosin in the treatment of HBeAg-negative chronic hepatitis B. ( Ozden, N; Saruc, M; Yuceyar, H, 2003) |
| "Lamivudine has been demonstrated to have consistent efficacy and safety in large-scale, phase III clinical trials." | 2.41 | Nucleoside analogues in the treatment of chronic hepatitis B. ( Leung, N, 2000) |
| "Due to its low efficacy, 40% in the treatment of chronic hepatitis B and 10-20% in the treatment of chronic hepatitis C, and to its adverse events, in some cases severe, new antiviric molecules are being investigated." | 2.40 | [New antiviral agents in the treatment of chronic hepatitis B and C]. ( Córdoba Cortijo, J; López Viedma, B; Olaso Peiró, V, 1998) |
| "Only one hepatocellular carcinoma developed, which was successfully treated by locoregional ablative therapy." | 1.33 | Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. ( Bara, C; Böker, KH; Deterding, K; Haverich, A; Manns, MP; Meyer, S; Pethig, K; Potthoff, A; Tillmann, HL; Wedemeyer, H, 2006) |
| "Lamivudine was effective also after famciclovir breakthrough in 94% of patients." | 1.31 | [Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases]. ( Bechstein, WO; Berg, T; Hopf, U; Langrehr, JM; Müller, AR; Naumann, U; Neuhaus, P; Neuhaus, R; Platz, KP; Rayes, N; Seehofer, D; Steinmüller, T, 2000) |
| "Lamivudine 3 mg/kg was administered on a compassionate-use basis for 14-36 months." | 1.31 | Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children. ( Bar-Nathan, N; Ben-Ari, Z; Dinari, G; Mor, E; Shapira, R; Sokal, EM; Tur-Kaspa, R, 2001) |
| "Medical therapy of chronic hepatitis B aims at halting progression towards cirrhosis/hepatocellular carcinoma by inhibiting replication of hepatitis B virus in a sustained fashion (viral elimination)." | 1.30 | [Drug therapy of chronic hepatitis B]. ( Lavanchy, D; Renner, EL, 1998) |
| "Prolonged therapy for chronic hepatitis B (HBV) with nucleoside analogs may result in the emergence of HBV mutants resistant to antivirals." | 1.30 | Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. ( Pichoud, C; Seignères, B; Trépo, C; Wang, Z; Zoulim, F, 1999) |
| "A consensus meeting on the treatment of chronic hepatitis B infection was conducted in Hong Kong, in August 1997." | 1.30 | Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective. ( Carman, WF; Lam, SK; Lau, GK; Locarnini, SA; Lu, ZM; Okuda, K; Williams, R, 1999) |
| "We described two chronic hepatitis B carriers (both hepatitis B e antigen negative), who cleared HBsAg after allogeneic bone marrow transplantation." | 1.30 | Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer. ( Au, WY; Lau, GK; Liang, R; Wu, PC; Yuen, ST, 1999) |
| "Lamivudine was well tolerated and liver function improved." | 1.30 | Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. ( Bechstein, WO; Budde, K; Hocher, B; Krüger, DH; Meisel, H; Neuhaus, P; Neumayer, HH; Preikschat, P; Reinke, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (30.00) | 18.2507 |
| 2000's | 42 (70.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Menne, S | 1 |
| Asif, G | 1 |
| Narayanasamy, J | 1 |
| Butler, SD | 1 |
| George, AL | 1 |
| Hurwitz, SJ | 1 |
| Schinazi, RF | 1 |
| Chu, CK | 1 |
| Cote, PJ | 1 |
| Gerin, JL | 3 |
| Tennant, BC | 3 |
| Lai, CL | 1 |
| Yuen, MF | 1 |
| Hui, CK | 1 |
| Garrido-Lestache, S | 1 |
| Cheng, CT | 1 |
| Lai, YP | 1 |
| Demirtürk, N | 1 |
| Usluer, G | 1 |
| Ozgünes, I | 1 |
| Colak, H | 1 |
| Kartal, ED | 1 |
| Dinçer, S | 1 |
| Papatheodoridis, GV | 1 |
| Dimou, E | 1 |
| Papadimitropoulos, V | 1 |
| Lim, SG | 1 |
| Wai, CT | 1 |
| Rajnakova, A | 1 |
| Kajiji, T | 1 |
| Guan, R | 1 |
| Wolters, LM | 3 |
| Hansen, BE | 1 |
| Niesters, HG | 3 |
| de Man, RA | 4 |
| Lackner, H | 1 |
| Moser, A | 1 |
| Benesch, M | 1 |
| Deutsch, J | 1 |
| Kessler, HH | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Dornbusch, HJ | 1 |
| Sovinz, P | 1 |
| Urban, C | 1 |
| Li, L | 2 |
| Shao, Q | 1 |
| Zhang, J | 1 |
| Ji, D | 1 |
| Ayres, A | 1 |
| Bartholomeusz, A | 1 |
| Lau, G | 1 |
| Lam, KC | 1 |
| Lee, JY | 1 |
| Locarnini, S | 3 |
| Wang, HF | 1 |
| Su, HB | 1 |
| Ji, W | 1 |
| Saruc, M | 1 |
| Ozden, N | 1 |
| Yuceyar, H | 1 |
| Lagget, M | 1 |
| Rizzetto, M | 1 |
| Delaney, WE | 1 |
| Yang, H | 1 |
| Westland, CE | 1 |
| Das, K | 1 |
| Arnold, E | 1 |
| Gibbs, CS | 2 |
| Miller, MD | 1 |
| Xiong, S | 1 |
| León, P | 1 |
| Pozo, F | 1 |
| Echevarría, JM | 1 |
| Shen, H | 1 |
| Alsatie, M | 1 |
| Eckert, G | 1 |
| Chalasani, N | 1 |
| Lumeng, L | 1 |
| Kwo, PY | 1 |
| Schiefke, I | 1 |
| Klecker, C | 1 |
| Maier, M | 1 |
| Oesen, U | 1 |
| Etzrodt, G | 1 |
| Tannapfel, A | 1 |
| Liebert, UG | 1 |
| Berr, F | 1 |
| Sagir, A | 1 |
| Avci, A | 1 |
| Erhardt, A | 1 |
| Lörke, J | 1 |
| Heintges, T | 1 |
| Häussinger, D | 1 |
| Wang, ZY | 1 |
| Guo, SH | 1 |
| Zhang, DF | 1 |
| Zhao, YR | 1 |
| Ren, H | 1 |
| Zhou, XQ | 1 |
| Xu, DZ | 1 |
| Sun, JY | 1 |
| Yao, JL | 1 |
| Lu, WL | 1 |
| Potthoff, A | 1 |
| Tillmann, HL | 3 |
| Bara, C | 1 |
| Deterding, K | 1 |
| Pethig, K | 2 |
| Meyer, S | 1 |
| Haverich, A | 2 |
| Böker, KH | 3 |
| Manns, MP | 4 |
| Wedemeyer, H | 2 |
| Krüger, M | 1 |
| Trautwein, C | 1 |
| Bode, U | 1 |
| Oldhafer, K | 1 |
| Maschek, H | 1 |
| Broelsch, CE | 1 |
| Pichlmayr, R | 1 |
| McCaughan, G | 1 |
| Angus, P | 1 |
| Bowden, S | 1 |
| Shaw, T | 2 |
| Breschkin, A | 1 |
| Sheil, R | 1 |
| Tassopoulos, NC | 1 |
| Olaso Peiró, V | 1 |
| López Viedma, B | 1 |
| Córdoba Cortijo, J | 1 |
| Honkoop, P | 1 |
| Jaeckel, E | 1 |
| Marques, AR | 1 |
| Lau, DT | 1 |
| McKenzie, R | 1 |
| Straus, SE | 1 |
| Hoofnagle, JH | 1 |
| Renner, EL | 1 |
| Lavanchy, D | 1 |
| Pichoud, C | 4 |
| Seignères, B | 2 |
| Wang, Z | 1 |
| Trépo, C | 6 |
| Zoulim, F | 5 |
| Main, J | 1 |
| McCarron, B | 1 |
| Thomas, HC | 1 |
| Lau, GK | 5 |
| Carman, WF | 2 |
| Locarnini, SA | 1 |
| Okuda, K | 1 |
| Lu, ZM | 1 |
| Williams, R | 1 |
| Lam, SK | 2 |
| Yuen, ST | 2 |
| Au, WY | 1 |
| Wu, PC | 1 |
| Liang, R | 1 |
| Meisel, H | 1 |
| Preikschat, P | 1 |
| Reinke, P | 1 |
| Hocher, B | 1 |
| Budde, K | 1 |
| Bechstein, WO | 3 |
| Neuhaus, P | 3 |
| Krüger, DH | 1 |
| Neumayer, HH | 1 |
| Young, CL | 1 |
| Hultgren, C | 1 |
| Weiland, O | 1 |
| Milich, DR | 1 |
| Sällberg, M | 1 |
| Petzold, DR | 1 |
| Flemming, P | 1 |
| Vollmar, J | 1 |
| Bastürk, M | 1 |
| Goldmann, E | 1 |
| Griffin, KE | 1 |
| Berby, F | 2 |
| Stuyver, L | 2 |
| Petit, MA | 1 |
| Ahmed, SS | 1 |
| Hantz, O | 1 |
| Freiman, JS | 1 |
| McCaughan, GW | 1 |
| Korba, BE | 2 |
| Cote, P | 2 |
| Hornbuckle, W | 2 |
| Schinazi, R | 1 |
| Zavaglia, C | 1 |
| Airoldi, A | 1 |
| Pinzello, G | 1 |
| Hou, J | 3 |
| Fen, X | 1 |
| Nie, Z | 1 |
| Jezek, P | 1 |
| Atkinson, G | 1 |
| Boon, R | 1 |
| Young, C | 2 |
| Tsiang, M | 1 |
| Yuen, S | 1 |
| Zhang, L | 1 |
| Lam, S | 1 |
| Marcellin, P | 1 |
| Habal, F | 1 |
| Desmond, P | 1 |
| Wright, T | 1 |
| Rose, T | 1 |
| Jurewicz, R | 1 |
| Leung, N | 1 |
| Nafa, S | 1 |
| Ahmed, S | 1 |
| Tavan, D | 1 |
| Johnson, M | 1 |
| Merle, P | 1 |
| Abidi, H | 1 |
| Seehofer, D | 2 |
| Rayes, N | 2 |
| Naumann, U | 1 |
| Neuhaus, R | 2 |
| Berg, T | 2 |
| Hopf, U | 1 |
| Langrehr, JM | 1 |
| Steinmüller, T | 1 |
| Platz, KP | 1 |
| Müller, AR | 2 |
| Suárez García, E | 1 |
| Romero Gómez, M | 1 |
| Grande Santamaría, L | 1 |
| Forns, X | 1 |
| Sánchez-Tapias, JM | 1 |
| Fried, MW | 1 |
| Sommadossi, JP | 1 |
| Shapira, R | 1 |
| Mor, E | 1 |
| Bar-Nathan, N | 1 |
| Sokal, EM | 1 |
| Tur-Kaspa, R | 1 |
| Dinari, G | 1 |
| Ben-Ari, Z | 1 |
| Perrillo, RP | 1 |
| Di Bisceglie, AM | 1 |
| Nanji, A | 1 |
| Fong, DY | 1 |
| Au, WS | 1 |
| Lin, M | 1 |
| Kung, HF | 1 |
17 reviews available for brl 42810 and Hepatitis B, Chronic
| Article | Year |
|---|---|
Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
Topics: 2-Aminopurine; Antiviral Agents; Cross Reactions; Drug Resistance, Viral; Famciclovir; Hepatitis B v | 2002 |
Thymosin in the treatment of HBeAg-negative chronic hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Hepatitis B e Antigens; Hep | 2003 |
Current pharmacotherapy for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B e Antig | 2003 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contrai | 2004 |
Chronic hepatitis B: interferon-monotherapy or combination with nucleoside analogues?
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Hepatitis B, Chronic; Human | 1998 |
[New antiviral agents in the treatment of chronic hepatitis B and C].
Topics: 2-Aminopurine; Antimetabolites; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Hepatitis B | 1998 |
Experience with lamivudine against hepatitis B virus.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; F | 1997 |
Treatment of chronic viral hepatitis.
Topics: 2-Aminopurine; Animals; Antimetabolites; Antiviral Agents; Carcinoma, Hepatocellular; Disease Models | 1998 |
New antiviral agents for the therapy of chronic hepatitis B virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Dr | 1999 |
Famciclovir update. Chronic hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Clinical Trials, Phase II as Topic; Famciclovir; Hepatitis B, Chron | 1999 |
Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; DNA, Viral; Famciclovir; Hepatitis B e Antigens; Hepatitis | 2000 |
Antiviral therapy of HBV- and HCV-induced liver cirrhosis.
Topics: 2-Aminopurine; Antiviral Agents; Clinical Trials as Topic; Famciclovir; Female; Hepatitis B, Chronic | 2000 |
Nucleoside analogues in the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Deoxycytidine; Emtricitabine; Famciclovir; Hepatitis B e A | 2000 |
Nucleoside analogues and other investigational modalities for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Arabinofuranosyluracil; Clinical Trials as Topic; Combined | 1996 |
Hepatitis B infection in China.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; China; Deoxycytidine; DNA, Viral; Drug Therapy, Combinatio | 2001 |
Nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Famciclovir; Ganciclovir; Guanine; Hepatitis B virus; Hepa | 2001 |
How will we use the new antiviral agents for hepatitis B?
Topics: 2-Aminopurine; Adenine; Alanine Transaminase; Antiviral Agents; Drug Resistance; Drug Therapy, Combi | 2002 |
16 trials available for brl 42810 and Hepatitis B, Chronic
| Article | Year |
|---|---|
Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Famciclovir; Female; Hepatiti | 2002 |
Comparison of different treatment combinations for chronic hepatitis B infection.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; | 2002 |
Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Female; Ganciclovir; | 2002 |
Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy.
Topics: 2-Aminopurine; Adolescent; Antiviral Agents; Child; Child, Preschool; DNA, Viral; Drug Therapy, Comb | 2002 |
[Famciclovir treatment of patients with chronic hepatitis B virus infection].
Topics: 2-Aminopurine; Adolescent; Aged; Antiviral Agents; Famciclovir; Female; Hepatitis B virus; Hepatitis | 2002 |
Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Adm | 2004 |
Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
Topics: 2-Aminopurine; Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents | 2004 |
[Clinical investigation of famciclovir in chronic hepatitis B patients irresponsive to alpha interferon treatment].
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Famciclovir; Female; Follow | 2005 |
Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Famciclovir; Female; | 1996 |
Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B.
Topics: 2-Aminopurine; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Vira | 1998 |
Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Therapy, Combin | 1999 |
Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
Topics: 2-Aminopurine; Adult; Amino Acid Sequence; Antiviral Agents; Cloning, Molecular; Drug Resistance, Mi | 2000 |
Famciclovir in chronic hepatitis B: results of a dose-finding study.
Topics: 2-Aminopurine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Dose-Response Relationship | 2000 |
Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Famciclov | 2000 |
A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Alanine Transaminase; DNA, Viral; Double-Blind Method; Famci | 2000 |
Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.
Topics: 2-Aminopurine; Adjuvants, Immunologic; Adolescent; Adult; Antiviral Agents; Cell Division; Cells, Cu | 2002 |
27 other studies available for brl 42810 and Hepatitis B, Chronic
| Article | Year |
|---|---|
Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Dioxolanes; DNA, Viral; Dose-Response Relationship, | 2007 |
Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resi | 2002 |
Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Famciclov | 2003 |
[Treatment of patients with chronic hepatitis B virus infect ion with lamivudine combined with famciclovir].
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Famciclo | 2003 |
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Topics: 2-Aminopurine; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Famciclovir; Hepatitis | 2003 |
Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
Topics: 2-Aminopurine; Amino Acid Sequence; Antiviral Agents; Diagnostic Tests, Routine; DNA Mutational Anal | 2004 |
Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Famciclovir; Female; Heart | 2006 |
Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy.
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Famciclovir; Follow-Up Studies; Ganciclovir; Graft Reje | 1996 |
Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene.
Topics: 2-Aminopurine; Alanine Transaminase; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Famc | 1998 |
[Drug therapy of chronic hepatitis B].
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Hepatitis B virus; Hepatitis B, Chronic; Humans; Inter | 1998 |
Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
Topics: 2-Aminopurine; Adult; Amino Acid Sequence; Antiviral Agents; Biomarkers; Cells, Cultured; Cloning, M | 1999 |
Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective.
Topics: 2-Aminopurine; Adjuvants, Immunologic; Animals; Antiviral Agents; Asia; Drug Therapy, Combination; F | 1999 |
Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer.
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Famciclovir; Hepati | 1999 |
Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine.
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Famciclovir; Follow-Up Studies; Genetic Variation; Hepa | 1999 |
Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection.
Topics: 2-Aminopurine; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Famciclovir; Hepatitis | 1999 |
Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B.
Topics: 2-Aminopurine; Antibodies, Viral; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Carrier State; Disease Models, Animal; Drug Therapy, Combi | 2000 |
Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Famciclovir; Hepatitis B Virus, Woodchuck; Hepatitis B, Ch | 2000 |
[Dynamic changes of hepatitis B virus during treatment with lamivudine versus lamivudine plus famciclovir].
Topics: 2-Aminopurine; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Female; | 2000 |
Combination chemotherapy for hepatitis B virus: the final solution?
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Drug Resistance; Drug Therapy, Combination; Famciclovir | 2000 |
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Aged, 80 and over; DNA, Viral; Drug Resistance, Microbial; D | 2000 |
[Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases].
Topics: 2-Aminopurine; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedu | 2000 |
Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
Topics: 2-Aminopurine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; Drug | 2000 |
[Current treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Anti-Inflammatory Agents; Antiviral Agents; DNA Replication; Famciclovir; Fo | 2001 |
[Laboratory diagnosis of hepatitis B].
Topics: 2-Aminopurine; Acute Disease; Antiviral Agents; DNA Replication; DNA, Viral; Drug Resistance; Famcic | 2001 |
Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children.
Topics: 2-Aminopurine; Adolescent; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Cystic F | 2001 |
Combination therapy for hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Forecasting; Hepatitis B, C | 2002 |